The study identifies distinct functional roles and interactions of SARS-CoV-2 N protein proteoforms, highlighting the C-terminal proteoform as a potential candidate for immune-directed therapies and cyclophilin A interaction as a therapeutic target.
Answers are grounded in this paper and cite their sources.
Should not alter COVID-19 care; extends N-protein biology in animals but leaves open human translation.
The SARS-CoV-2 nucleocapsid (N) protein is a highly immunogenic viral protein that plays essential roles in replication and virion assembly. Here, using native mass spectrometry, we show that dimers are the functional unit of ribonucleoprotein assembly and that N protein binds RNA with a preference for GGG motifs, a common motif in coronavirus packaging signals. Unexpectedly, proteolytic processing of N protein resulted in the formation of additional proteoforms. The N-terminal proteoforms bind RNA, with the same preference for GGG motifs, and bind to cyclophilin A, an interaction which can be abolished by approved immunosuppressant cyclosporin A. Furthermore, N proteoforms showed significantly different interactions with IgM, IgG, and IgA antibodies from convalescent plasma. Notably, the C-terminal proteoform exhibited a heightened interaction with convalescent antibodies, suggesting the antigenic epitope is localized to the C-terminus. Overall, the different interactions of N proteoforms highlight potential avenues for therapeutic intervention and identify a stable and immunogenic proteoform as a possible candidate for immune-directed therapies.
No takes yet. Share an insight, caveat, or question.
Lutomski et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: